258 related articles for article (PubMed ID: 20558734)
1. Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL.
Pierroz DD; Bonnet N; Baldock PA; Ominsky MS; Stolina M; Kostenuik PJ; Ferrari SL
J Biol Chem; 2010 Sep; 285(36):28164-73. PubMed ID: 20558734
[TBL] [Abstract][Full Text] [Related]
2. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL.
Kostenuik PJ; Nguyen HQ; McCabe J; Warmington KS; Kurahara C; Sun N; Chen C; Li L; Cattley RC; Van G; Scully S; Elliott R; Grisanti M; Morony S; Tan HL; Asuncion F; Li X; Ominsky MS; Stolina M; Dwyer D; Dougall WC; Hawkins N; Boyle WJ; Simonet WS; Sullivan JK
J Bone Miner Res; 2009 Feb; 24(2):182-95. PubMed ID: 19016581
[TBL] [Abstract][Full Text] [Related]
3. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing.
Gerstenfeld LC; Sacks DJ; Pelis M; Mason ZD; Graves DT; Barrero M; Ominsky MS; Kostenuik PJ; Morgan EF; Einhorn TA
J Bone Miner Res; 2009 Feb; 24(2):196-208. PubMed ID: 19016594
[TBL] [Abstract][Full Text] [Related]
4. Effects of denosumab, alendronate, or denosumab following alendronate on bone turnover, calcium homeostasis, bone mass and bone strength in ovariectomized cynomolgus monkeys.
Kostenuik PJ; Smith SY; Samadfam R; Jolette J; Zhou L; Ominsky MS
J Bone Miner Res; 2015 Apr; 30(4):657-69. PubMed ID: 25369992
[TBL] [Abstract][Full Text] [Related]
5. Effect of RANKL-specific denosumab on osteoclast number and function: a potential friend or foe?
Tankó LB
Curr Opin Investig Drugs; 2007 Oct; 8(10):830-5. PubMed ID: 17907059
[TBL] [Abstract][Full Text] [Related]
6. The anabolic action of intermittent PTH in combination with cathepsin K inhibitor or alendronate differs depending on the remodeling status in bone in ovariectomized mice.
Yamane H; Sakai A; Mori T; Tanaka S; Moridera K; Nakamura T
Bone; 2009 Jun; 44(6):1055-62. PubMed ID: 19303837
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with ONO-KK1-300-01, a cathepsin K inhibitor, and parathyroid hormone results in additive beneficial effect on bone mineral density in ovariectomized rats.
Ochi Y; Yamada H; Mori H; Kawada N; Tanaka M; Imagawa A; Ohmoto K; Kawabata K
J Bone Miner Metab; 2016 Jan; 34(1):33-40. PubMed ID: 25762435
[TBL] [Abstract][Full Text] [Related]
8. Resorption controls bone anabolism driven by parathyroid hormone (PTH) receptor signaling in osteocytes.
Rhee Y; Lee EY; Lezcano V; Ronda AC; Condon KW; Allen MR; Plotkin LI; Bellido T
J Biol Chem; 2013 Oct; 288(41):29809-20. PubMed ID: 23963454
[TBL] [Abstract][Full Text] [Related]
9. CREM deficiency in mice alters the response of bone to intermittent parathyroid hormone treatment.
Liu F; Lee SK; Adams DJ; Gronowicz GA; Kream BE
Bone; 2007 Apr; 40(4):1135-43. PubMed ID: 17275432
[TBL] [Abstract][Full Text] [Related]
10. Accentuated osteoclastic response to parathyroid hormone undermines bone mass acquisition in osteonectin-null mice.
Machado do Reis L; Kessler CB; Adams DJ; Lorenzo J; Jorgetti V; Delany AM
Bone; 2008 Aug; 43(2):264-273. PubMed ID: 18499553
[TBL] [Abstract][Full Text] [Related]
11. Beta-Arrestin2 regulates RANKL and ephrins gene expression in response to bone remodeling in mice.
Pierroz DD; Rufo A; Bianchi EN; Glatt V; Capulli M; Rucci N; Cavat F; Rizzoli R; Teti A; Bouxsein ML; Ferrari SL
J Bone Miner Res; 2009 May; 24(5):775-84. PubMed ID: 19113915
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with a beta-blocker and intermittent PTH improves bone mass and microarchitecture in ovariectomized mice.
Pierroz DD; Bouxsein ML; Rizzoli R; Ferrari SL
Bone; 2006 Aug; 39(2):260-7. PubMed ID: 16531131
[TBL] [Abstract][Full Text] [Related]
13. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
[TBL] [Abstract][Full Text] [Related]
14. Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
J Bone Miner Res; 2007 Jan; 22(1):55-63. PubMed ID: 17014384
[TBL] [Abstract][Full Text] [Related]
15. Denosumab, a fully human RANKL antibody, reduced bone turnover markers and increased trabecular and cortical bone mass, density, and strength in ovariectomized cynomolgus monkeys.
Ominsky MS; Stouch B; Schroeder J; Pyrah I; Stolina M; Smith SY; Kostenuik PJ
Bone; 2011 Aug; 49(2):162-73. PubMed ID: 21497676
[TBL] [Abstract][Full Text] [Related]
16. Continuous elevation of PTH increases the number of osteoblasts via both osteoclast-dependent and -independent mechanisms.
Jilka RL; O'Brien CA; Bartell SM; Weinstein RS; Manolagas SC
J Bone Miner Res; 2010 Nov; 25(11):2427-37. PubMed ID: 20533302
[TBL] [Abstract][Full Text] [Related]
17. Pretreatment with anticatabolic agents blunts but does not eliminate the skeletal anabolic response to parathyroid hormone in oophorectomized mice.
Samadfam R; Xia Q; Goltzman D
Endocrinology; 2007 Jun; 148(6):2778-87. PubMed ID: 17379647
[TBL] [Abstract][Full Text] [Related]
18. Unexpected Bone Formation Produced by RANKL Blockade.
Portal-Núñez S; Mediero A; Esbrit P; Sánchez-Pernaute O; Largo R; Herrero-Beaumont G
Trends Endocrinol Metab; 2017 Oct; 28(10):695-704. PubMed ID: 28733136
[TBL] [Abstract][Full Text] [Related]
19. Intermittent Parathyroid Hormone After Prolonged Alendronate Treatment Induces Substantial New Bone Formation and Increases Bone Tissue Heterogeneity in Ovariectomized Rats.
Altman-Singles AR; Jeong Y; Tseng WJ; de Bakker CM; Zhao H; Lott C; Robberts J; Qin L; Han L; Kim DG; Liu XS
J Bone Miner Res; 2017 Aug; 32(8):1703-1715. PubMed ID: 28467646
[TBL] [Abstract][Full Text] [Related]
20. Characterization, pharmacokinetics, and pharmacodynamics of anti-Siglec-15 antibody and its potency for treating osteoporosis and as follow-up treatment after parathyroid hormone use.
Tsuda E; Fukuda C; Okada A; Karibe T; Hiruma Y; Takagi N; Isumi Y; Yamamoto T; Hasegawa T; Uehara S; Koide M; Udagawa N; Amizuka N; Kumakura S
Bone; 2022 Feb; 155():116241. PubMed ID: 34715394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
